Is PT-141 FDA approved? It depends on which product you mean. Bremelanotide, the drug name for PT-141, is FDA-approved under the brand Vyleesi for one narrow use: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 is not FDA-approved. The approval also does not cover men or enhancing sexual performance. Most conflicting answers online come from mixing up the molecule, the branded product and compounded preparations.
Key takeaways
- Bremelanotide is FDA-approved as Vyleesi, and that approval covers only acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
- The label states that Vyleesi is not indicated for men, for postmenopausal women or to enhance sexual performance.
- Compounded PT-141 contains the same active ingredient as Vyleesi, but it is not FDA-approved and FDA does not review it before it reaches patients.
- A compounded prescription and a "research use only" vial are different things: one requires a prescription and a licensed pharmacy, and the other sits outside that system.
- PT-141 acts on the nervous system, not on blood flow, and blood pressure and heart health should be screened before any prescription.
Is PT-141 FDA approved? The short answer
Bremelanotide is FDA-approved as Vyleesi, an injection indicated for premenopausal women with acquired, generalized HSDD (FDA Vyleesi label, 2026). HSDD is low sexual desire that causes marked distress or interpersonal difficulty. Compounded PT-141 is not FDA-approved, because compounded drugs as a category are not FDA-approved (FDA, Human Drug Compounding Laws).
Pages that answer with a flat yes are usually stretching Vyleesi's approval to every product with the same ingredient. Pages that answer with a flat no are usually ignoring the approved product. Both are half-right, so this article keeps the categories apart.
Scope: this covers regulatory status and the injectable format. It contains no dosing information. Dosing decisions belong to an independent licensed clinician; follow your clinician's guidance and pharmacy instructions.
PT-141, bremelanotide and Vyleesi: one molecule, three labels
PT-141 and bremelanotide are the same molecule under two names, and Vyleesi is one specific approved product that contains it.
- PT-141 is the earlier research code name.
- Bremelanotide is the nonproprietary drug name.
- Vyleesi is the brand name of an FDA-approved bremelanotide injection given under the skin, with an initial U.S. approval in 2019 (FDA Vyleesi label, 2026).
FDA's approval package shows an approval date of June 21, 2019, under new drug application (NDA) 210557 (FDA approval package, 2019). An NDA is the formal application a manufacturer submits for FDA to review a new drug's safety and effectiveness.
FDA approval attaches to a specific product, maker, formulation and indication, not to a molecule in general. A compounded preparation containing bremelanotide is not Vyleesi. Saying it has the same active ingredient as Vyleesi is accurate. Calling it equivalent to Vyleesi, a generic version or "the same as" Vyleesi is not.
What FDA actually approved Vyleesi for
Vyleesi is indicated for premenopausal women with acquired, generalized HSDD, where low desire causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance (FDA Vyleesi label, 2026).
The label defines its two key terms:
- Acquired HSDD develops in someone who previously had no problems with sexual desire.
- Generalized HSDD occurs regardless of the type of stimulation, situation or partner.
The approval rested on two phase 3 trials. These were identical 24-week randomized, double-blind, placebo-controlled studies known as RECONNECT (Obstet Gynecol, 2019). Together they enrolled 1,247 premenopausal women with acquired, generalized HSDD, with a mean age of 39 (FDA Vyleesi label, 2026).
Bremelanotide showed statistically significant improvement over placebo on both co-primary endpoints: the desire domain of the Female Sexual Function Index (FSFI) and a distress item from the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) (FDA Vyleesi label, 2026).
The limits matter just as much:
- There was no significant difference between groups in the number of satisfying sexual events, a secondary endpoint (FDA Vyleesi label, 2026). A post hoc analysis in the published trials also found no significant difference (Obstet Gynecol, 2019).
- More people stopped early on the drug. Premature discontinuation was 40% versus 13% in Study 1 and 39% versus 25% in Study 2. Discontinuation due to adverse reactions was 18% on drug versus 2% on placebo (FDA Vyleesi label, 2026).
So "Vyleesi improved sexual satisfaction" is not what the trials showed. They showed improvement in measured desire and distress scores.
Is PT-141 approved for men or for sexual performance?
No. The label's Limitations of Use state that Vyleesi is not indicated for HSDD in men or in postmenopausal women, and not indicated to enhance sexual performance (FDA Vyleesi label, 2026). The patient leaflet adds that it is not for use in children.
A note on terms: off-label is not the same as unapproved. Off-label use means a clinician prescribes an FDA-approved product for a use not listed on its label. A compounded bremelanotide preparation is a separate product that FDA has not approved for any use (FDA, Human Drug Compounding Laws). "PT-141 is approved for men off-label" therefore mixes two different ideas.
Research in men is older and limited. A randomized, double-blind, placebo-controlled trial enrolled 342 men aged 28 to 59 with erectile dysfunction who had not responded to sildenafil (J Urol, 2008). It used a different formulation from Vyleesi, and the authors concluded that further studies were needed before drawing final conclusions. The journal has since published an Expression of Concern about the study. This trial marks a limit on the evidence, not support for use in men.
Whether PT-141 is appropriate for any adult is a clinical decision. An independent licensed clinician makes it based on your intake and clinical review. Not everyone qualifies, and that's how it should work.
What "compounded, not FDA-approved" actually means
It means FDA has not reviewed the product for safety, effectiveness or quality before it reaches patients (FDA, Human Drug Compounding Laws). Compounding is a legal pathway with its own rules, but it is not a shortcut to FDA approval.
FDA says compounded drugs can serve an important role for patients whose clinical needs cannot be met by an FDA-approved drug. FDA also says compounded drugs pose a higher risk to patients than approved drugs (FDA 503A prescription guidance).
Two sections of federal law set the rules:
- Section 503A covers compounding by a licensed pharmacist or physician (FDA essentially-copies guidance). The drug must be compounded on a valid patient-specific prescription (FDA, Human Drug Compounding Laws). 503A compounders are not licensed by FDA and generally do not register with FDA, and FDA is often unaware of problems unless it receives a complaint (FDA 503A prescription guidance).
- Section 503B covers compounding by outsourcing facilities (FDA essentially-copies guidance).
Both sections restrict compounding of products that are essentially copies of a commercially available drug (503A) or an approved drug (503B), according to the same FDA guidance. That is why "a cheaper Vyleesi" is the wrong way to describe compounded PT-141.
In short, compounded PT-141 is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities, and it is not FDA-approved. Vyleesi's trials do not establish the safety of a compounded preparation. For more on the two oversight models, see 503A vs 503B oversight and quality.
Compounded prescription vs research-chemical PT-141
A compounded prescription and a "research use only" vial are not the same product category. The first runs through a clinician and a licensed pharmacy. The second is sold outside the prescription and pharmacy system, so none of the 503A or 503B conditions apply to it.
| Feature | FDA-approved Vyleesi | Compounded PT-141 prescription | "Research use only" PT-141 |
|---|---|---|---|
| FDA-approved product | Yes, for one indication | No | No |
| FDA pre-market review of safety, effectiveness and quality | Yes | No | No |
| Prescription required | Yes | Yes, valid and patient-specific | No |
| Who prepares it | Manufacturer under NDA 210557 | State-licensed 503A pharmacy or FDA-registered 503B facility | Unknown seller |
| Blood pressure and heart screening before use | Label calls for it | Should be part of clinical review | None |
| Oversight path | FDA approval and labeling | State licensing and federal compounding rules | Outside the prescription and pharmacy system |
Before trusting any source, run four checks:
- Is a licensed clinician writing a prescription for you specifically?
- Is the dispensing pharmacy named and licensed?
- Did a clinician screen your blood pressure and heart health?
- Does the product say "research use only" or "not for human consumption"? If so, it is outside the system entirely.
How PT-141 works, and why screening comes first
PT-141 acts on the nervous system, not on blood flow. Bremelanotide is a melanocortin receptor agonist, meaning it activates melanocortin receptors. The label lists MC1R and MC4R as most relevant at therapeutic doses, and notes that MC4R neurons are present in many areas of the central nervous system (FDA Vyleesi label, 2026). The label also says the mechanism by which it improves HSDD in women is unknown.
That sets it apart from PDE5 inhibitors such as tadalafil, which work by increasing blood flow. The PT-141 vs tadalafil comparison covers the differences.
Blood pressure and heart health are the main screening concern. The label reports that bremelanotide transiently increases blood pressure and lowers heart rate after each dose, usually returning to baseline within 12 hours. It is contraindicated in uncontrolled hypertension and known cardiovascular disease. It is not recommended for people at high cardiovascular risk, and blood pressure should be well controlled before starting (FDA Vyleesi label, 2026). This is why, before PT-141, an independent licensed clinician screens blood pressure and heart health as part of clinical review.
Other label points, briefly: nausea was the most common adverse reaction; focal darkening of the skin was reported and may not resolve after stopping; and it may slow stomach emptying, which can affect oral medicines. The label also says to avoid it with oral naltrexone products for alcohol or opioid addiction. Full detail is in PT-141 side effects from label data.
These data describe Vyleesi in premenopausal women. They do not transfer automatically to compounded preparations or to other groups.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
- You complete a structured online intake.
- An independent licensed clinician reviews it, including blood pressure and heart health. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
- If appropriate and prescribed, compounded PT-141 is prepared by a state-licensed 503A compounding pharmacy or FDA-registered 503B outsourcing facility, and a licensed partner pharmacy ships the medication directly to you.
The pathway is injectable only. Compounded PT-141 is not FDA-approved. Availability varies by state; check state availability. Care is for adults 21 and older and is not for emergencies. New Blue is LegitScript certified.
If you're not prescribed after the online review, all of what you paid comes back. If your state needs a video visit, everything except the cost of that visit comes back. Details are in the refund policy. For current pricing, see the PT-141 treatment page.
Frequently Asked Questions
Is PT-141 FDA approved?
Bremelanotide, the drug in PT-141, is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women (FDA Vyleesi label, 2026). Compounded PT-141 is not FDA-approved (FDA, Human Drug Compounding Laws).
Are PT-141 and bremelanotide the same thing?
Yes, they are the same molecule. PT-141 is the earlier research name and bremelanotide is the drug name. Vyleesi is one specific FDA-approved bremelanotide product, and a compounded preparation containing bremelanotide is not Vyleesi.
What did FDA approve Vyleesi for?
Vyleesi is approved for acquired, generalized HSDD in premenopausal women. The label excludes men, postmenopausal women and use to enhance sexual performance (FDA Vyleesi label, 2026).
Is PT-141 approved for men?
No. The Vyleesi label states it is not indicated for HSDD in men (FDA Vyleesi label, 2026). Research in men is older and limited, and one randomized trial in men now carries a journal Expression of Concern (J Urol, 2008).
Is compounded PT-141 legal?
Compounding by a state-licensed 503A pharmacy on a valid patient-specific prescription, or by an FDA-registered 503B outsourcing facility, is a recognized pathway under federal law (FDA, Human Drug Compounding Laws). The compounded product is still not FDA-approved. Rules and availability also vary by state.
Does Vyleesi's FDA approval mean compounded PT-141 is safe?
No. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients (FDA, Human Drug Compounding Laws). Vyleesi's trial and safety data describe the approved product in premenopausal women, not compounded preparations.
Is PT-141 the same as tadalafil?
No. PT-141 acts on the nervous system, while tadalafil works on blood flow and is the active ingredient in Cialis, FDA-approved for erectile dysfunction and symptoms of benign prostatic hyperplasia (BPH). Tadalafil must not be combined with nitrate medications. Both require clinician screening before a prescription.
Sources
- VYLEESI (bremelanotide injection), for subcutaneous use: Full Prescribing Information and Patient Information (Revised 10/2026). U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf
- Approval Package for Application Number 210557Orig1s000: Vyleesi (bremelanotide) subcutaneous injection. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599840/
- Human Drug Compounding Laws. U.S. Food and Drug Administration, no date listed. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. U.S. Food and Drug Administration, no date listed. https://www.fda.gov/files/drugs/published/Prescription-Requirement-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
- Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the FD&C Act: Guidance for Industry. U.S. Food and Drug Administration, no date listed. https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
- Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of Urology, 2008. https://pubmed.ncbi.nlm.nih.gov/18206919/
Medical disclaimer: This article is educational and is not medical advice. Treatment decisions, including whether any medication is appropriate, are made by an independent licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.